Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 5/20 | 0.37 |
| ▸ | SYK | P43405 | 7/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847840 | 0.85 | SYK (0.41) | BTKCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL2100940 | 0.83 | MAPK8 (0.45) | BTKCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL847586 | 0.83 | MAPK8 (0.45) | BTKCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL848330 | 0.83 | MAPK8 (0.45) | BTKCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL848652 | 0.80 | KDM4E (0.43) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL847497 | 0.80 | SYK (0.45) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL849073 | 0.79 | MAPK8 (0.49) | SYKJAK2JAK3 | |
| SCHEMBL847489 | 0.76 | OPRK1 (0.45) | PDE4BSYKIRAK4 | |
| SCHEMBL26038535 | 0.71 | IRAK4 (0.38) | BTKSYKJAK2PDE7AIRAK4 | |
| SCHEMBL846834 | 0.70 | MAPK8 (0.41) | SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | BTK 562/4885CHRM3 308/4885PDE4A 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.